Reassessing the 1 + 1 pneumococcal conjugate vaccine schedule – Authors' reply

David Goldblatt, Elizabeth Miller

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)382-383
Number of pages2
JournalThe Lancet Infectious Diseases
Issue number4
Publication statusPublished - Apr 2018

Bibliographical note

Funding Information:
DG has served on ad-hoc advisory boards for GSK, Merck, and Sanofi, and is a National Institute of Health Research (NIHR) Senior Investigator. DG's laboratory has received contract research funding from GSK, Merck, and Sanofi. EM declares no competing interests.

Cite this